Social media

From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase. Explore oncology case studies: https://ow.ly/2Xqk50WY1mg

From molecule to market - see how ICON supports oncology sponsors with tailored strategies, from logistics to regulatory, across every phase. Explore oncology case studies: https://ow.ly/Jjhf50WY1mh

ICON is pleased to invite you to an upcoming webinar titled “Introducing ICON strategic solutions FSP services: How this model supports sponsors in Korea,” taking place on 28 October at 2:00 PM KST. This session will pro...

ICON is pleased to invite you to an upcoming webinar titled “Introducing ICON strategic solutions FSP services: How this model supports sponsors in Korea,” taking place on 28 October at 2:00 PM KST. This session will pro...

ICON’s Mia Carter joins a panel on Investigational Drug Accountability Management to discuss the real-world friction between clinical sites and sponsors and how to overcome it. Topics include regulatory alignment, effici...

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

Why do stability studies matter in early drug development? From shelf-life determination to regulatory readiness, a well-designed stability program ensures your drug product remains safe, effective, and reliable. Learn...

ICON will participate in the upcoming Medical Technology Enterprise Consortium (MTEC) webinar on 15 October from 1:00 pm to 2:00 pm. Timothy Bradshaw, Ph.D. and Edward Wright will speak on the topic: "Advancing ICON ea...

ICON will participate in the upcoming Medical Technology Enterprise Consortium (MTEC) webinar on 15 October from 1:00 pm to 2:00 pm. Tim Bradshaw and Edward Wright will speak on the topic: "Advancing ICON early-stage c...

Connect with the ICON team during ACR Convergence 2025 at booth \#1501, to discover how Accellacare—our Global Site Network with deep expertise in osteoarthritis, osteoporosis, and rheumatoid arthritis—supports sponsors ...

Biosimilars are gaining ground in APAC — but adoption depends on education. ICON’s latest blog dives into the real-world barriers to biosimilar uptake across Asia-Pacific, from low patient awareness to prescriber miscon...

Biosimilars are positively impacting healthcare in APAC — but awareness and trust remain critical hurdles. ICON explores how strategic education and engagement can unlock biosimilar adoption across Asia-Pacific, from em...